2型糖尿病治療における治療薬の処方状況と処方理由を調査するため，2型糖尿病患者を1ヵ月に10人以上診察する医師500人を対象に，糖尿病治療薬に関するアンケート調査を行った。糖尿病治療の第一選択薬はDPP-4阻害薬が最も多く，ビグアナイド薬，SGLT2阻害薬が続いた。診療科別では専門医でビグアナイド薬，循環器科でSGLT2阻害薬が多く選択される傾向にあった。薬剤選択における重要視項目は「低血糖をきたしにくい」が最も多く，次いで「重篤な副作用がない」「血糖降下作用が強い」「心血管イベント抑制効果」が挙げられた。近年の糖尿病治療薬選択の傾向として心血管イベント抑制効果を重視する傾向がみられた。

This study was conducted to investigate prescription patterns and reasons of using antidiabetic drugs in Japan. Data was collected using online survey system and 500 doctors who have more than 10 diabetes patients per month participated in this study. A dipeptidyl peptidase-4 inhibitors (DPP-4i) were the most selected for first-line drugs, followed by biguanides and sodium glucose co-transporter 2 inhibitors (SGLT2i). Biguanides were more commonly selected by specialists, whereas SGLT2i were more selected by cardiologists. Low risk of causing hypoglycemia or severe adverse effects, high glucose-lowering effects, and potential cardiovascular protective actions were reasons why these antidiabetic drugs were prescribed. The present results suggest that most of the clinicians would prescribe antidiabetic drugs to intend to reduce the cardiovascular event risk.